MTNB - Matinas BioPharma Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.9000
-0.0012 (-0.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.9012
Open0.9233
Bid0.8800 x 1000
Ask0.9089 x 900
Day's Range0.8733 - 0.9233
52 Week Range0.4900 - 2.4900
Volume1,019,906
Avg. Volume1,948,698
Market Cap177.738M
Beta (5Y Monthly)2.82
PE Ratio (TTM)N/A
EPS (TTM)-0.1170
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Matinas BioPharma to Present at the Jefferies Virtual Healthcare Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a company overview during the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 8:00 a.m. ET. Investors interested in arranging a virtual meeting with the Company's management during this conference should contact the conference coordinator. A live webcast of the panel discussion will be available on the IR Calendar page of the Investors  section of the Company’s website (www.matinasbiopharma.com).

  • Insider Buying: The Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Independent Vice Chairman of the Board Just Bought 33% More Shares
    Simply Wall St.

    Insider Buying: The Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Independent Vice Chairman of the Board Just Bought 33% More Shares

    Whilst it may not be a huge deal, we thought it was good to see that the Matinas BioPharma Holdings, Inc...

  • Will Matinas BioPharma Continue to Surge Higher?
    Zacks

    Will Matinas BioPharma Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor of Matinas BioPharma

  • Thomson Reuters StreetEvents

    Edited Transcript of MTNB earnings conference call or presentation 11-May-20 8:30pm GMT

    Q1 2020 Matinas BioPharma Holdings Inc Earnings Call

  • Matinas Biopharma Holdings Inc (MTNB) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    Matinas Biopharma Holdings Inc (MTNB) Reports Q1 Loss, Misses Revenue Estimates

    Matinas Biopharma Holdings Inc (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Matinas BioPharma Reports First Quarter 2020 Financial Results and Operational Highlights

    – ENHANCE-IT study of MAT9001 against Vascepa® set to resume in June 2020 – – EnACT study of MAT2203 in cryptococcal meningitis expected to resume in June 2020 – – Management.

  • GlobeNewswire

    Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2020 Financial and Operational Results on May 11, 2020

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, May 11, 2020 at 4:30 p.m. ET to discuss operational and financial results for the first quarter ended March 31, 2020. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions.

  • GlobeNewswire

    Matinas BioPharma to Participate in Panel Discussion During Maxim Group Infectious Disease Virtual Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a panel discussion, as well as host investor meetings, during the Maxim Group Infectious Disease Virtual Conference. Investors interested in arranging a virtual meeting with the Company's management during this conference should contact the conference coordinator, Soraya Dorce (sdorce@maximgrp.com). A live audio webcast of the panel discussion will be available on the Events page of the Investors section of the Company’s website (www.matinasbiopharma.com) and at M-Vest.

  • Thomson Reuters StreetEvents

    Edited Transcript of MTNB earnings conference call or presentation 9-Mar-20 12:00pm GMT

    Q4 2019 Matinas BioPharma Holdings Inc Earnings Call

  • Investors Who Bought Matinas BioPharma Holdings (NYSEMKT:MTNB) Shares Three Years Ago Are Now Down 81%
    Simply Wall St.

    Investors Who Bought Matinas BioPharma Holdings (NYSEMKT:MTNB) Shares Three Years Ago Are Now Down 81%

    Every investor on earth makes bad calls sometimes. But really bad investments should be rare. So take a moment to...

  • GlobeNewswire

    Matinas BioPharma Provides Comment on Impact of Vascepa® Patent Litigation on MAT9001 and Update on COVID-19 Pandemic’s Effect on Business Operations and Clinical Programs

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today commented on the recent United States District Court decision to invalidate patents related to Amarin Corporation’s Vascepa and also provided an update on the effect of the rapidly evolving COVID-19 pandemic on its business operations and clinical development programs. Matinas is aware of the United States District Court for the District of Nevada’s ruling yesterday in favor of the generic companies in Amarin Corporation’s patent litigation against two filers of abbreviated new drug applications, or ANDAs, for Amarin’s Vascepa.

  • Matinas Biopharma Holdings, Inc. (MTNB) Reports Q4 Loss, Misses Revenue Estimates
    Zacks

    Matinas Biopharma Holdings, Inc. (MTNB) Reports Q4 Loss, Misses Revenue Estimates

    Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of -33.33% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Matinas BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

    Initiated ENHANCE-IT study of MAT9001 against Vascepa®. Topline data expected Q4 2020 Initiated efficacy phase of NIH-funded EnACT study of MAT2203 in cryptococcal meningitis.

  • ACCESSWIRE

    Matinas Biopharma Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 9, 2020 / Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March ...

  • The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
    Benzinga

    The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues

    Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccine news. View more earnings on IBBThe following are key catalysts in the unfolding week that a biotech investor should stay tuned to. Conferences Barclays Global Healthcare Conference: March 10-12 in Miami, Florida. American Academy of Allergy Asthma and Immunology, or AAAAI, Annual Meeting: March 13-16 in Philadelphia, Pennsylvania.PDUFA Dates The FDA is set to rule on Bristol-Myers Squibb Co's (NYSE: BMY) sBLA for Opdivo \+ Yervoy as a treatment option for patients with advanced hepatocellular carcinoma who were previously treated with Bayer AG (OTC: BAYRY) and Onyx Pharma's Nexavar. The PDUFA date has been set for Tuesday.Clinical Readouts Blueprint Medicines Corp (NASDAQ: BPMC) is scheduled to present at the AAAAI annual meeting with Phase 2 data for Avapritinib, which is being evaluated for treating indolent and smoldering systemic mastocytosis.See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Earnings Monday * Matinas BioPharma Holdings Inc (NYSE: MTNB) (before the market open) * Minerva Neurosciences Inc (NASDAQ: NERV) (before the market open) * BioXcel Therapeutics Inc (NASDAQ: BTAI) (before the market open) * Assertio Therapeutics Inc (NASDAQ: ASRT) (after the close) * SI-Bone Inc (NASDAQ: SIBN) (after the close) * Xenon Pharmaceuticals Inc (NASDAQ: XENE) (after the close) * Organogenesis Holdings Inc (NASDAQ: ORGO) (after the close) * Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) (after the close)Tuesday * Precision BioSciences Inc (NASDAQ: DTIL) (time not provided) * Akebia Therapeutics Inc (NASDAQ: AKBA) (before the market open) * Catabasis Pharmaceuticals Inc (NASDAQ: CATB) (before the market open) * InspireMD Inc (NYSE: NSPR) (before the market open) * ChemoCentryx Inc (NASDAQ: CCXI) (after the close) * CV Sciences Inc (OTC: CVSI) (after the close) * Fulgent Genetics Inc (NASDAQ: FLGT) (after the close) * Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) (after the close) * RA Medical Systems Inc (NYSE: RMED) (after the close) * Protagonist Therapeutics Inc (NASDAQ: PTGX) (after the close)Wednesday * Xeris Pharmaceuticals Inc (NASDAQ: XERS) (before the market open) * Liquidia Technologies Inc (NASDAQ: LQDA) (before the market open) * Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) (before the market open) * INmune Bio Inc (NASDAQ: INMB) (before the market open) * Clearside Biomedical Inc (NASDAQ: CLSD) (after the close) * Calithera Biosciences Inc (NASDAQ: CALA) (after the close) * Unity Biotechnology Inc (NASDAQ: UBX) (after the close) * Navidea Biopharmaceuticals Inc (NYSE: NAVB) (after the close) * Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (after the close) * BioLife Solutions Inc (NASDAQ: BLFS) (after the close) * Dynavax Technologies Corporation (NASDAQ: DVAX) (after the close) * Miragen Therapeutics Inc (NASDAQ: MGEN) (after the close) * Pfenex Inc (NYSE: PFNX) (after the close) * Thursday * Aquestive Therapeutics Inc (NASDAQ: AQST) (before the market open) * Avadel Pharmaceuticals PLC (NASDAQ: AVDL) (before the market open) * Axsome Therapeutics Inc (NASDAQ: AXSM) (before the market open) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) (before the market open) * Selecta Biosciences Inc (NASDAQ: SELB) (before the market open) * Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) (before the market open) * Provention Bio Inc (NASDAQ: PRVB) (before the market open) * Protalix Biotherapeutics Inc (NYSE: PLX) (before the market open) * Evofem Biosciences Inc (NASDAQ: EVFM) (before the market open) * China Biologic Products Holdings Inc (NASDAQ: CBPO) (before the market open) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) (before the market open) * Pieris Pharmaceuticals Inc (NASDAQ: PIRS) (before the market open) * X4 Pharmaceuticals Inc (NASDAQ: XFOR) (before the market open) * Polarityte Inc (NASDAQ: PTE) (before the market open) * Rubius Therapeutics Inc (NASDAQ: RUBY) (before the market open) * Agenus Inc (NASDAQ: AGEN) (before the market open) * ADMA Biologics Inc (NASDAQ: ADMA) (after the close) * BioDelivery Sciences International, Inc. (NASDAQ: BDSI) (after the close) * Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) (after the close) * Celcuity Inc (NASDAQ: CELC) (after the close) * Lineage Cell Therapeutics Inc (NYSE: LCTX) (after the close) * Chembio Diagnostics Inc (NASDAQ: CEMI) (after the close) * Harpoon Therapeutics Inc (NASDAQ: HARP) (after the close) * Flexion Therapeutics Inc (NASDAQ: FLXN) (after the close) * Neoleukin Therapeutics Inc (NASDAQ: NLTX) (after the close) * Rockwell Medical Inc (NASDAQ: RMTI) (after the close) * Inovio Pharmaceuticals Inc (NASDAQ: INO) (after the close) * Savara Inc (NASDAQ: SVRA) (after the close) * Ocular Therapeutix Inc (NASDAQ: OCUL) (after the close) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) (after the close)Friday * PLx Pharma Inc (NASDAQ: PLXP) (before the market open) * Achieve Life Sciences Inc (NASDAQ: ACHV) (before the market open)IPOs Imara, a biopharma company that is developing therapies for rare hemoglobinopathies, has filed to offer 4.45 million shares in an IPO, to be priced between $16 and $18. The company seeks to list its shares on the Nasdaq under the ticker symbol "IMRA."IPO Quiet Period Expiry Revolution Medicines Inc (NASDAQ: RVMD)Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors See more from Benzinga * The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study * The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19 * The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Matinas BioPharma Announces Initiation of ENHANCE-IT Study of MAT9001 Against Vascepa®

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has initiated the ENHANCE-IT Study (Pharmacodynamic Effects of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Efficacy in Adults with Hypertriglyceridemia), a head-to-head pharmacodynamic (PD) study of MAT9001 against Vascepa® in patients with elevated triglycerides (150-499 mg/dL). The ENHANCE-IT study will assess MAT9001’s effectiveness in reducing triglyceride levels and other important lipid markers, as well as gather important data on bioavailability and blood levels of eicosapentaenoic acid (EPA) and other omega-3 fatty acids. “The ENHANCE-IT study is a significant next step in our clinical development program designed to highlight the impressive efficacy of MAT9001 and further distinguish its superior profile from Vascepa,” commented James J. Ferguson, M.D., Chief Medical Officer of Matinas.

  • GlobeNewswire

    Matinas BioPharma Appoints James A. Underberg, M.D. to its MAT9001 Scientific Advisory Board

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB) today announced the appointment of James A. Underberg, M.D., M.S., FACPM, FACP, FNYAM, FASPC, FNLA to its Scientific Advisory Board (SAB). Dr. Underberg is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease.

  • GlobeNewswire

    Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Operational and Financial Results on March 9, 2020

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, March 9, 2020 at 8:00 a.m. ET to discuss operational and financial results for the fourth quarter and full year ended December 31, 2019. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions.

  • GlobeNewswire

    Matinas BioPharma Announces DSMB Approval to Commence Part 2 of EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that the independent Data Safety Monitoring Board (DSMB) for the EnACT study has completed its planned review of initial safety and tolerability data from the Part 1 dose escalation phase and unanimously approved proceeding with enrollment in the Part 2 efficacy phase at 2g of MAT2203 daily, the highest dose tested in Part 1. The 2g dose will be tested in the 2-week induction phase of treatment. Part 2 of the EnACT study will explore the use of MAT2203 for both induction and maintenance therapy in HIV-patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immunocompromised individuals.

  • Analysts: These 3 Penny Stocks Are Positioned for Big Gains in 2020
    TipRanks

    Analysts: These 3 Penny Stocks Are Positioned for Big Gains in 2020

    Penny stocks, you either love them or you hate them. One of the obvious draws of these stocks trading for under $5 per share is the ability to get more bang for your buck. And should these bargain priced stocks see their share prices rise by only a small amount, the rewards can be staggering.However, before jumping right into an investment in a penny stock, Wall Street pros advise looking at the bigger picture and considering other factors beyond just the price tag. For some names that fall into this category, you really do get what you pay for, offering little in the way of long-term growth prospects thanks to weak fundamentals, recent headwinds or even large outstanding share counts.Taking all of this into consideration, we used TipRanks’ Stock Screener tool to zero in on the crème-de-la-crème when it comes to penny stocks. We are referring to the names that have not only received substantial support from Wall Street analysts but also boast sky-high upside potential from their current levels. Let's take a closer look.Matinas BioPharma Holdings (MTNB) Through the development of its lead candidate, MAT9001, Matinas BioPharma wants to offer new treatments for cardiovascular and metabolic conditions. MAT9001 is an omega-3 fatty acid-based drug designed as a more effective hypertriglyceridemia treatment. With it well positioned in an expanding market, SunTrust Robinson analyst Gregg Gilbert believes that at $1.35 per share, now is the time to buy.Despite having struggled year-to-date, investors shouldn’t panic according to the analyst. MTNB’s descent was partly related to the early success of its competitor Amarin’s Vascepa, its omega-3 fatty acid drug, as its label expansion to include cardiovascular risk reduction was just approved in December. However, Gilbert actually sees Vascepa’s launch as a positive for MTNB.Gilbert cites the growth of the omega-3 class as the source of his optimism. Currently, there are only two prescription omega-3s to reduce triglycerides in patients with severe hypertriglyceridemia available in the U.S., Lovaza and Vascepa. As more and more research is conducted, the evidence in support of the benefits of omega-3s is mounting, implying that there’s plenty of room for MTNB to take market share.On top of this, Gilbert points out that MAT9001 is unique in that it contains EPA and DPA in free fatty acid form and is highly bioavailable. Based on early clinical data, the drug’s composition has been shown to produce substantial reductions in lipid markers and higher bioavailability compared to Vascepa. “While a few years from market, we believe MAT9001 could carve out a nice slice of the omega-3 market given its unique characteristics,” the analyst commented.While noting that it’s difficult to gauge the size of the omega-3 market, about 4 million patients are candidates for Lovaza or Vascepa based on the indication for severe hypertriglyceridemia. With the recent expansion of Vascepa’s label, the opportunity could be further expanded.All of the above prompted Gilbert to kick off his MTNB coverage by issuing a bullish call. At his $3 price target, shares could be in for a 122% gain over the next twelve months. (To watch Gilbert’s track record, click here)What does the rest of the Street think? As it turns out, all 5 of the analysts that have published a recent review see the stock as a Buy, making the consensus rating a unanimous Strong Buy. Adding to the good news, the $3.30 average price target indicates 144% upside potential. (See Matinas BioPharma price targets and analyst ratings on TipRanks)Marrone Bio Innovations (MBII) For Marrone Bio, sustainability is the name of the game. The company uses microorganisms isolated from samples collected from flowers, insects, soil and composts to find effective solutions for pest management and plant health. Currently trading for $1.14 per share, some argue that this price can only go up from here.During the first three quarters of 2019, the company was able to report revenue growth of 46% year-to-date. However, its disappointing bottom line results have worried investors. Even with the revenue gains, earnings haven’t improved. That being said, National Securities analyst Ben Klieve thinks that MBII’s financials are in for a change. He cites its investments in several growth initiatives as potentially fueling reductions in adjusted EBITDA losses.Additionally, Klieve highlights the improvements in both gross margins and gross profit and new collaborations with Corteva and Compass Minerals as being encouraging signs. “We believe this momentum can continue into the fourth quarter and carry into 2020. With organic growth being supplemented by the acquisition of Pro Farm, we expect revenue growth can again approach 50% in 2020 with continued progress in gross margins,” he explained.Based on the company’s efforts to drive a turnaround, Klieve kept both his Buy rating and $2.50 price target as is. This implies that shares could climb 119% higher in the next twelve months. (To watch Klieve’s track record, click here)Meanwhile, Amit Dayal of H.C. Wainwright points to the EPA’s recent approval of two of its biofungicide products, Stargus and Regalia, for use on hemp plants as reaffirming his bullish thesis. Since 2018, no other crop protection products have been given the thumbs up for use on hemp. Not to mention the company estimates the hemp market in 2018 reached over $1.1 billion and could more than double by 2022.“We believe that being the first company with EPA approved crop protection products for use in hemp–in addition to these products being bio-based–affords Marrone a significant competitive advantage,” Dayal commented. Thanks to this development, the analyst reiterated his bullish call. At $2.50, his price target mirrors Klieve’s. (To watch Dayal’s track record, click here)When it comes to other analyst activity, it has been relatively quiet on Wall Street. The two analysts above have published the only recent reviews, making the consensus rating a Moderate Buy. (See Marrone Bio stock analysis on TipRanks)TETRA Technologies (TTI)Switching gears now, TETRA provides the upstream energy industry with solutions for completion fluids and water management as well as offers various compression services. According to one analyst, its price tag of $1.51 a share is a steal.B.Riley FBR’s Tom Curran does acknowledge that its onshore NAM OFS businesses, especially water and flowback's services in the Permian, continue to face challenges, and its long-term hydrochloric acid (HCI) supply agreement impacts the value of its mechanical evaporation (ME) plant in the near-term. Having said that, he argues TTI has a lot going for it. During a recent conference, management stated that the operator who awarded it the CS Neptune project should have started completions activity during Q4 2019, beginning the consumption of product under the contract.Curran argues that this would be a huge step forward, writing, “Although there is a real possibility that the completion phase did not start until later in 4Q19 and could spill over into 1Q20, we believe that the mere commencement of Neptune sales under this contract should be a significant positive for both TTI's stock sentiment and fundamental story, especially since the product is so lucrative that even a modest amount of revenue recognition should have a pronounced impact on the division's margin.”He concluded by noting, “We continue to like TTI's cheap valuation, which we suspect is partly due to misperceptions about TTI-only's actual debt burden; Completion Fluids division's promising CS Neptune product suite and structurally increasing profitability; and Water & Flowback division's potential to significantly rebound as competitive improvements converge with a cyclical upswing.”To this end, Curran maintained a Buy recommendation. Despite reducing the price target from $3.75 to $3.50, he still believes a 132% twelve-month gain could be in store. (To watch Curran’s track record, click here)Looking at the consensus breakdown, only one other analyst has thrown an opinion into the mix. However, the rating was also bullish, making the Street consensus a Moderate Buy. While lower than Curran’s forecast, the $2.88 average price target still suggests huge upside potential of 91%. (See TETRA stock analysis on TipRanks)

  • 5 Stocks Under $5 With Colossal Growth Prospects
    InvestorPlace

    5 Stocks Under $5 With Colossal Growth Prospects

    Investors want to see a return on investment, it's as simple as that. Regardless of the size of the investment, the end goal remains the same. Sure, there are several ways to go about achieving this objective, yet time after time Wall Street observers circle back to a single tried and true strategy.Growth investing involves identifying the stocks with long-term growth prospects that go above and beyond those of their peers.It should be noted, though, that plays in the growth-stock arena can sometimes come with a price tag to match their huge potential for gains. However, there are compelling names out there that don't cost a fortune.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWhile some naysayers might argue that you get what you pay for, others will point out that stocks trading at low levels can represent some of the most compelling names on the Street, with entry points that make them even more attractive. * 7 Stocks to Buy for February Contrarians With this in mind, I used TipRanks' Stock Screener tool during my own search for affordable growth names. After sorting the results by current share price, analyst consensus and price target, the tool revealed three stocks that have received a wealth of support from Wall Street analysts, all under $5 per share. To top it all off, each boasts massive upside potential from current levels. Matinas BioPharma (MTNB)Source: Shutterstock Like the name suggests, Matinas BioPharma Holdings (NYSE MKT:MTNB) is a biopharma focused on the development of lead candidate, MAT9001, its prescription-only omega-3 fatty acid drug for cardiovascular and metabolic conditions. After the FDA approved the label expansion of Amarin's Vascepa drug to include cardiovascular disease patients with high triglycerides of greater than 150 mg/dL, some analysts believe that MTNB's $1.44 share price is a bargain.Piper Sandler analyst Edward Tenthoff tells investors that his bullish thesis is primarily driven by earlier data published by MTNB. Back in 2015, the company reported that during a Phase 1 study, MAT9001 was found to have produced a greater reduction of triglycerides, with the figure coming in at 33% compare to Vascapa's 11%.The drug is currently being evaluated in the Phase 2 ENHANCE-IT study versus Vascepa. With data slated for release in the fourth quarter of this year, big things could be on the way. Tenthoff argues MTNB could start a single Phase 3 severe hypertriglyceridemia trial in 2021 and see potential approval in 2023. In addition, he thinks that the importance of omega-3-based medicines is expanding.All of the above factors prompted the analyst to start his MTNB coverage by publishing an "overweight" rating and setting a $3 price target. Should the target be met, shares could be in for a 108% gain over the next twelve months.Similarly, the rest of the Street takes a bullish approach when it comes to MTNB. Out of four analysts tracking the name over the last three months, 100% see the stock as a "buy," making the consensus rating a "strong buy." Given the $3.25 average price target, the upside potential of 126% surpasses Tenthoff's estimate. See the MTNB stock analysis. Northern Oil And Gas (NOG)Source: Shutterstock Northern Oil and Gas (NYSE MKT:NOG) is one of the primary non-operator franchises in the Bakken and Three Forks plays in the Williston Basin of North Dakota and Montana. Its total footprint, which lands at about 165,000 acres, as well as its proved reserves of 65.3 million barrels of oil equivalent at year-end 2015, has helped cement its status as one of the leading players in the space. Its $1.69 price tag seems almost too good to be true.Back in December, the company gave investors a reason to get excited after it announced that it would start paying out a quarterly dividend. The first dividend will come in at two cents per share, payable in April 2020. In addition, the forward yield lands at 3.14%.This news prompted Imperial Capital analyst Jason Wangler to boost his rating from "in-line" to "outperform." He argues that while the dividend is modest, it demonstrates that NOG has taken steps in the right direction in terms of its balance sheet over the last two years. On top of this, it also means that the name can be thought of as a yield vehicle.It makes sense, then, that in addition to the upgrade, Wangler bumped up the price target from $2 to $2.50. At this new target, the upside potential comes in at 48%. * 7 Under-the-Radar European Stocks to Buy for 2020 When it comes to other analyst activity, it has been relatively quiet on Wall Street. That being said, the two other analysts that published a review in the last three months rated NOG as a "buy," making the Street consensus a "strong buy." Not to mention the $3.25 average price target brings the upside potential to 92%. See the NOG stock analysis. Durect Corporation (DRRX) Source: Shutterstock Durect Corporation (NASDAQ:DRRX) has a simple objective: to transform medicine. It wants to develop drugs that can provide meaningful advances in patient health and wellbeing. At the bargain price of $2.12 per share, analysts warn investors that if they wait too long, they could miss out on the opportunity.While investor concern has definitely emerged, Craig-Hallum analyst Francois Brisebois is still very much on board. Fears among investors have been driven by the company's announcement that the AdCom vote for its Posimir drug's Class 2 New Drug Application (NDA) resubmission was split right down the middle.As a result, Brisebois doesn't assign any value to the drug in the model. Rather, he highlights its DUR-928 candidate for primary alcoholic hepatitis as DRRX's primary value driver, calling early efficacy and safety data incredibly encouraging. On top of this, the analyst argues that the combination of the current poor standard of care and the $3 billion total addressable market played into his conclusion that investors should buy on any weakness.With this in mind, Brisebois kicked off his DRRX coverage by issuing a "buy" rating. In addition, he set a Street high price target of $6, implying a staggering 183% upside potential.Meanwhile, the rest of the Street also likes what it's seeing. A "strong buy" consensus rating breaks down into three "buys" and a single "hold." While less aggressive than that of Brisebois, the $4.65 average price target still puts the potential twelve month gain at 119%. See the DRRX stock analysis. Carrols Restaurant Group (TAST)Source: Shutterstock While the name Carrols Restaurant Group (NASDAQ:TAST) might not ring any bells, but you've probably heard of its restaurants Burger King and Popeyes. It is true that shares took a pretty substantial hit following its preliminary fourth quarter results. Now at just $4.80 apiece, Deutsche Bank's Brian Mullan is still in the restaurant company's corner.The negative reaction came largely as a result of Burger King's same store sales (SSS) results. At 2%, the figure falls well below the implied guidance's range of 4% to 5% range and reflects a deceleration in November and December.However, Mullan tells investors that there's a silver lining. Management noted that the focus will shift towards managing both net leverage levels and free cash flow. "While management wasn't explicit with its plans, reading the tea leaves our sense is that these comments could pertain to either: 1) a reduced pace of acquisitions for the foreseeable future, 2) a potential slowdown in new unit development, or 3) all of the above," he explained.This combined with the new CFO appointment implies that the plans for the above are "… fluid and evolving. We think the key takeaway here is that management is mindful of the market's perception of TAST's net leverage levels, and that it has several options at its disposal to address this, should it see fit," Mullan added.Taking all of this into consideration, the analyst left his "buy" rating and $8 price target as is. This means that shares could potentially surge 67% in the next twelve months. * 7 Biometrics Stocks That Will Help Shape the Next Decade Judging by the consensus breakdown, the rest of the Street is in agreement. With only "buy" ratings assigned in the last three months, the message is clear: TAST is a "strong buy." It also doesn't hurt that the $8.83 average price target suggests 84% upside potential. See the TAST stock analysis. VBI Vaccines (VBIV)Source: Shutterstock VBI Vaccines' (NASDAQ:VBIV) claim to fame is its Sci-B-Vac product, which was the first vaccine to be commercially-approved for hepatitis B. The vaccine is currently available in Israel and ten other countries. It recently completed its Phase 3 program in the U.S., Europe and Canada. After new data was released earlier this month, analysts have been impressed, to say the least.On Jan. 9, the company, which goes for $1.46 a share, announced that Sci-B-Vac had met both its primary and secondary endpoints in the second Pivotal Phase 3 CONSTANT study. Both management and investors were excited by the results as they demonstrate that the candidate is both safe and highly-potent.While this outcome is encouraging, VBIV's potential extends beyond Sci-B-Vac. BMO Capital analyst Do Kim highlights its VBI-1901 and VBI-2601 candidates as potentially driving significant upside. According to the analyst, updated Phase 1/2a tumor response and survival data for VBI-1901's use in glioblastoma multiforme (GMB) is slated for release some time in the first half of 2020. Should the results be favorable, VBIV could develop a modified version to target other EBV+ cancers. On top of this, VBI-2601 proof-of-concept for use in chronic hepatitis B infection (HBV) is expected in the second half of the year."We believe the initial data could be meaningful for VBI's vaccine approach for a functional HBV cure, with the potential for combining beyond antivirals, including Brii's VIR-2218 and other HBsA RNAi. With an estimated 257 million chronically infected patients worldwide, we believe HBV represents a significant market opportunity for a functional cure," Kim commented.Based on everything the healthcare name has going for it, Kim reiterated his "outperform" rating and $5 price target, indicating 242% upside potential.Out of three total analysts that have thrown their hat in with a review, 100% sided with the bulls, making the consensus rating a "strong buy." See the VBIV stock analysis.TipRanks offers investors the latest insight into eight different sectors by tracking the activity of over 5,000 Wall Street analysts. As of this writing, Maya Sasson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy for February Contrarians * 10 of the Top Franchise Stocks to Buy Now * 5 High-Yield Stocks With High Free Cash Flow Yields The post 5 Stocks Under $5 With Colossal Growth Prospects appeared first on InvestorPlace.

  • Prospects Appear Bright for Small Drug Industry in 2020
    Zacks

    Prospects Appear Bright for Small Drug Industry in 2020

    Prospects Appear Bright for Small Drug Industry in 2020

  • GlobeNewswire

    Matinas BioPharma Announces Closing of Public Offering of Common Stock

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the closing  of its underwritten registered public offering of 32,260,000 shares of its common stock, offered at a price to the public of $1.55 per share for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Matinas BioPharma has granted the underwriters a 30-day option to purchase up to an additional 4,839,000 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Matinas BioPharma.

  • GlobeNewswire

    Matinas BioPharma Announces Pricing of Public Offering of Common Stock

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten registered public offering of 32,260,000 shares of its common stock, offered at a price to the public of $1.55 per share for expected gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Matinas BioPharma has granted the underwriters a 30-day option to purchase up to an additional 4,839,000 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Matinas BioPharma.

  • Benzinga

    The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...